‘Pharma Bro’ Martin Shkreli Defends Palantir’s Valuation Amid 24% Surge, Says AI Firm’s Cash Flow Justifies ‘Expensive’ Price

Martin Shkreli, the former hedge fund manager known as “Pharma Bro,” defended Palantir Technologies Inc.’s valuation on Tuesday amid the company’s surging stock price, projecting substantial cash flow growth for the data analytics firm through 2025.

read more

Leave a Reply

Your email address will not be published. Required fields are marked *